Friday, December 24, 2021 9:30:12 AM
Can you post the exact verbiabe? Sorry for the trouble, but I am quite curious. It is baffling to me that people can’t see what is going on from a Marketing perspective. Consider it a three legged table.
First, despite not presenting any new Congress information for like 2 or 3 years, LL has actually provided a heck of a lot of peer reviewed content at various institutions and CME events. The scientific strategy for statistical analysis, data base construction, and a large volume of actual clinical data inclusive of combo patient cases and no less than 5 actual live responders. Meanwhile, a peer reviewed publication or three gets submitted to a top tier journal.
Next, you have the Unbranded, disease and mechanism of disease work, alongside pipeline forward looking statements in booth and in other venue. Then a shift towards separation of disease materials from other material in space (at congress) and time (full page, quarter page advertisement). The unbranded advertisement lists claims that if directly attributed to a branded product would be efficacy, safety, durability, and a suggestion of approval, but alas it is unbranded.
Then, a Branded campaign of DCVax (R) with only disease and mechanism. No opportunity for contiguous link to Unbranded campaign as booth gets removed from congress. Unbranded remains in IBTA print separated from Branded in ABTA program and at SNO. Where else will Branding be employed? Oh, yea in the updated Franhoufer PR from 2012.
Then comes Mernix. In which bucket does that one fall?
This is becoming from the land of sky blue waters…
Fully Kroisened, from White Mountain Springs and Chippewa Falls.
Here is to good friends, tonight is kind of special!
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
